Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitors.
Wu, B., Wang, H.L., Cee, V.J., Lanman, B.A., Nixey, T., Pettus, L., Reed, A.B., Wurz, R.P., Guerrero, N., Sastri, C., Winston, J., Lipford, J.R., Lee, M.R., Mohr, C., Andrews, K.L., Tasker, A.S.(2015) Bioorg Med Chem Lett 25: 775-780
- PubMed: 25616902 
- DOI: https://doi.org/10.1016/j.bmcl.2014.12.091
- Primary Citation of Related Structures:  
4WSY, 4WT6 - PubMed Abstract: 
PIM kinases are a family of Ser/Thr kinases that are implicated in tumorigenesis. The discovery of a new class of PIM inhibitors, 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines, is discussed with optimized compounds showing excellent potency against all three PIM isoforms.
Organizational Affiliation: 
Department of Therapeutic Discovery, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799, USA. Electronic address: binw@amgen.com.